Last 12 months
Inside the activity.
0 purchase rows · 6 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2022 Filed Feb 22, 2022 22:34 UTC |
Durkin Brian LVP, Controller
|
GrantCommon Stock, $0.01 par value | 2,754 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001510 · edgar.xml · nonDerivative · entry 4 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,629 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:34 UTC |
Durkin Brian LVP, Controller
|
GrantCommon Stock, $0.01 par value | 3,743 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001510 · edgar.xml · nonDerivative · entry 3 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,875 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:34 UTC |
Durkin Brian LVP, Controller
|
GrantCommon Stock, $0.01 par value | 1,897 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001510 · edgar.xml · nonDerivative · entry 2 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,132 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:34 UTC |
Durkin Brian LVP, Controller
|
GrantCommon Stock, $0.01 par value | 8,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001510 · edgar.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,235 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:39 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
GrantOption (right to buy) · Derivative | 30,647 | $0.00 Strike: $144.54 | $0.00 |
DisclosureSEC source: 0001179110-22-001513 · edgar.xml · derivative · entry 7 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,647 Underlying: Common Stock · 30,647 shares Expires 2032-02-16 F7 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,216 on February 17, 2023, 10,216 on February 17, 2024, and 10,215 on February 17, 2025. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:39 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
GrantCommon Stock, $0.01 par value | 8,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001513 · edgar.xml · nonDerivative · entry 4 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,779 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:39 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
GrantCommon Stock, $0.01 par value | 14,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001513 · edgar.xml · nonDerivative · entry 3 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,078 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:39 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
GrantCommon Stock, $0.01 par value | 7,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001513 · edgar.xml · nonDerivative · entry 2 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,356 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:39 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
GrantCommon Stock, $0.01 par value | 36,673 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001513 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,384 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:40 UTC |
RICHMOND TIMOTHY J.EVP, Chief HR Officer
|
GrantOption (Right to Buy) · Derivative | 35,026 | $0.00 Strike: $144.54 | $0.00 |
DisclosureSEC source: 0001179110-22-001516 · edgar.xml · derivative · entry 6 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,026 Underlying: Common Stock · 35,026 shares Expires 2032-02-16 F6 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,676 on February 17, 2023, 11,675 on February 17, 2024, and 11,675 on February 17, 2025. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:40 UTC |
RICHMOND TIMOTHY J.EVP, Chief HR Officer
|
GrantCommon Stock, $0.01 par value | 13,837 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001516 · edgar.xml · nonDerivative · entry 5 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,296 F5 · shares: Represents shares of AbbVie common stock issued under a cliff vesting restricted stock unit award granted to the reporting person on February 17, 2022. The shares will vest in their entirety on the third anniversary of the grant date, subject to the reporting person's continued employment at AbbVie on such date. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:40 UTC |
RICHMOND TIMOTHY J.EVP, Chief HR Officer
|
GrantCommon Stock, $0.01 par value | 7,490 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001516 · edgar.xml · nonDerivative · entry 4 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,459 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:40 UTC |
RICHMOND TIMOTHY J.EVP, Chief HR Officer
|
GrantCommon Stock, $0.01 par value | 11,978 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001516 · edgar.xml · nonDerivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,969 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:40 UTC |
RICHMOND TIMOTHY J.EVP, Chief HR Officer
|
GrantCommon Stock, $0.01 par value | 4,998 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001516 · edgar.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,991 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:40 UTC |
RICHMOND TIMOTHY J.EVP, Chief HR Officer
|
GrantCommon Stock, $0.01 par value | 22,993 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001516 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,993 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 17:39 UTC |
Michael Robert A.Vice Chairman
|
GrantOption (Right to Buy) · Derivative | 48,161 | $0.00 Strike: $144.54 | $0.00 |
DisclosureSEC source: 0001179110-22-001515 · edgar.xml · derivative · entry 5 Michael Robert A. · CIK 0001699914 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,161 Underlying: Common Stock · 48,161 shares Expires 2032-02-16 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,054 on February 17, 2023, 16,054 on February 17, 2024, and 16,053 on February 17, 2025. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 17:39 UTC |
Michael Robert A.Vice Chairman
|
GrantCommon Stock, $0.01 par value | 11,565 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001515 · edgar.xml · nonDerivative · entry 4 Michael Robert A. · CIK 0001699914 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,268 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were release d on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 17:39 UTC |
Michael Robert A.Vice Chairman
|
GrantCommon Stock, $0.01 par value | 16,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001515 · edgar.xml · nonDerivative · entry 3 Michael Robert A. · CIK 0001699914 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,703 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 17:39 UTC |
Michael Robert A.Vice Chairman
|
GrantCommon Stock, $0.01 par value | 8,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001515 · edgar.xml · nonDerivative · entry 2 Michael Robert A. · CIK 0001699914 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,483 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 17:39 UTC |
Michael Robert A.Vice Chairman
|
GrantCommon Stock, $0.01 par value | 40,749 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001515 · edgar.xml · nonDerivative · entry 1 Michael Robert A. · CIK 0001699914 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,626 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:40 UTC |
SALEKI-GERHARDT AZITAEVP, Operations
|
GrantOption (Right to Buy) · Derivative | 35,026 | $0.00 Strike: $144.54 | $0.00 |
DisclosureSEC source: 0001179110-22-001517 · edgar.xml · derivative · entry 8 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,026 Underlying: Common Stock · 35,026 shares Expires 2032-02-16 F8 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,676 on February 17, 2023, 11,675 on February 17, 2024, and 11,675 on February 17, 2025. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:40 UTC |
SALEKI-GERHARDT AZITAEVP, Operations
|
GrantCommon Stock, $0.01 par value | 13,837 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001517 · edgar.xml · nonDerivative · entry 5 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,020 F5 · shares: Represents shares of AbbVie common stock issued under a cliff vesting restricted stock unit award granted to the reporting person on February 17, 2022. The shares will vest in their entirety on the third anniversary of the grant date, subject to the reporting person's continued employment at AbbVie on such date. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:40 UTC |
SALEKI-GERHARDT AZITAEVP, Operations
|
GrantCommon Stock, $0.01 par value | 7,490 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001517 · edgar.xml · nonDerivative · entry 4 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,183 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:40 UTC |
SALEKI-GERHARDT AZITAEVP, Operations
|
GrantCommon Stock, $0.01 par value | 11,229 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001517 · edgar.xml · nonDerivative · entry 3 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,693 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:40 UTC |
SALEKI-GERHARDT AZITAEVP, Operations
|
GrantCommon Stock, $0.01 par value | 5,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001517 · edgar.xml · nonDerivative · entry 2 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,464 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:40 UTC |
SALEKI-GERHARDT AZITAEVP, Operations
|
GrantCommon Stock, $0.01 par value | 25,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001517 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,896 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:42 UTC |
Sorg Elaine K.SVP, US Commercial Operations
|
GrantOption (Right to Buy) · Derivative | 18,388 | $0.00 Strike: $144.54 | $0.00 |
DisclosureSEC source: 0001179110-22-001518 · edgar.xml · derivative · entry 6 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,388 Underlying: Common Stock · 18,388 shares Expires 2032-02-16 F6 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,130 on February 17, 2023, 6,129 on February 17, 2024, and 6,129 on February 17, 2025. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:42 UTC |
Sorg Elaine K.SVP, US Commercial Operations
|
GrantCommon Stock, $0.01 par value | 10,377 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001518 · edgar.xml · nonDerivative · entry 5 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,485 F5 · shares: Represents shares of AbbVie common stock issued under a cliff vesting restricted stock unit award granted to the reporting person on February 17, 2022. The shares will vest in their entirety on the third anniversary of the grant date, subject to the reporting person's continued employment at AbbVie on such date. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:42 UTC |
Sorg Elaine K.SVP, US Commercial Operations
|
GrantCommon Stock, $0.01 par value | 4,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001518 · edgar.xml · nonDerivative · entry 4 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,108 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:42 UTC |
Sorg Elaine K.SVP, US Commercial Operations
|
GrantCommon Stock, $0.01 par value | 6,861 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001518 · edgar.xml · nonDerivative · entry 3 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,033 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:42 UTC |
Sorg Elaine K.SVP, US Commercial Operations
|
GrantCommon Stock, $0.01 par value | 2,530 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001518 · edgar.xml · nonDerivative · entry 2 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,172 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:42 UTC |
Sorg Elaine K.SVP, US Commercial Operations
|
GrantCommon Stock, $0.01 par value | 11,642 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001518 · edgar.xml · nonDerivative · entry 1 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,642 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:42 UTC |
Stewart Jeffrey RyanEVP, Chief Commercial Officer
|
GrantOption (Right to Buy) · Derivative | 37,215 | $0.00 Strike: $144.54 | $0.00 |
DisclosureSEC source: 0001179110-22-001519 · edgar.xml · derivative · entry 7 Stewart Jeffrey Ryan · CIK 0001761675 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,215 Underlying: Common Stock · 37,215 shares Expires 2032-02-16 F7 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,405 on February 17, 2023, 12,405 on February 17, 2024, and 12,405 on February 17, 2025. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:42 UTC |
Stewart Jeffrey RyanEVP, Chief Commercial Officer
|
GrantCommon Stock, $0.01 par value | 13,837 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001519 · edgar.xml · nonDerivative · entry 5 Stewart Jeffrey Ryan · CIK 0001761675 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,522 F5 · shares: Represents shares of AbbVie common stock issued under a cliff vesting restricted stock unit award granted to the reporting person on February 17, 2022. The shares will vest in their entirety on the third anniversary of the grant date, subject to the reporting person's continued employment at AbbVie on such date. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:42 UTC |
Stewart Jeffrey RyanEVP, Chief Commercial Officer
|
GrantCommon Stock, $0.01 par value | 7,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001519 · edgar.xml · nonDerivative · entry 4 Stewart Jeffrey Ryan · CIK 0001761675 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,685 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:42 UTC |
Stewart Jeffrey RyanEVP, Chief Commercial Officer
|
GrantCommon Stock, $0.01 par value | 7,486 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001519 · edgar.xml · nonDerivative · entry 3 Stewart Jeffrey Ryan · CIK 0001761675 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,975 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:42 UTC |
Stewart Jeffrey RyanEVP, Chief Commercial Officer
|
GrantCommon Stock, $0.01 par value | 4,176 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001519 · edgar.xml · nonDerivative · entry 2 Stewart Jeffrey Ryan · CIK 0001761675 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,489 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:42 UTC |
Stewart Jeffrey RyanEVP, Chief Commercial Officer
|
GrantCommon Stock, $0.01 par value | 19,209 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001519 · edgar.xml · nonDerivative · entry 1 Stewart Jeffrey Ryan · CIK 0001761675 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,313 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:42 UTC |
Strom Carrie CSVP & Pres Global Allerg Aesth
|
GrantOption(Right to Buy) · Derivative | 24,080 | $0.00 Strike: $144.54 | $0.00 |
DisclosureSEC source: 0001179110-22-001520 · edgar.xml · derivative · entry 2 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,080 Underlying: Common Stock · 24,080 shares Expires 2032-02-16 F2 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,027 on February 17, 2023, 8,027 on February 17, 2024, and 8,026 on February 17, 2025. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:42 UTC |
Strom Carrie CSVP & Pres Global Allerg Aesth
|
GrantCommon Stock, $0.01 par value | 5,727 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001520 · edgar.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,226 F1 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 07, 2022 Filed Feb 8, 2022 22:13 UTC |
Strom Carrie CSVP & Pres Global Allerg Aesth
|
Exercise / conversionOption (right to buy) · Derivative | 4,184 | $0.00 Strike: $47.27 | $0.00 |
DisclosureSEC source: 0001179110-22-000922 · edgar.xml · derivative · entry 3 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,184 shares Expires 2022-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 07, 2022 Filed Feb 8, 2022 22:13 UTC |
Strom Carrie CSVP & Pres Global Allerg Aesth
|
SaleCommon Stock, $0.01 par value | 2,396 | $141.17 | $338,243.32 |
DisclosureSEC source: 0001179110-22-000922 · edgar.xml · nonDerivative · entry 2 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,499 Read SEC document |
| February 07, 2022 Filed Feb 8, 2022 22:13 UTC |
Strom Carrie CSVP & Pres Global Allerg Aesth
|
GrantCommon Stock, $0.01 par value | 4,184 | $47.27 | $197,777.68 |
DisclosureSEC source: 0001179110-22-000922 · edgar.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,895 Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 22:02 UTC |
Alpern Robert JDirector
|
GrantStock Equivalent Units · Derivative | 53 | $135.40 Strike: $135.40 | $7,176.20 |
DisclosureSEC source: 0001179110-22-000118 · edgar.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,210 Underlying: Common Stock · 53 shares Expires not disclosed F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 22:02 UTC |
RAPP EDWARD JDirector
|
GrantStock Equivalent Units · Derivative | 260 | $135.40 Strike: $135.40 | $35,204.00 |
DisclosureSEC source: 0001179110-22-000119 · edgar.xml · derivative · entry 1 RAPP EDWARD J · CIK 0001171780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,434 Underlying: Common Stock · 260 shares Expires not disclosed F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 17:03 UTC |
LIDDY EDWARD MDirector
|
GrantStock Equivalent Units · Derivative | 212 | $135.40 Strike: $135.40 | $28,704.80 |
DisclosureSEC source: 0001179110-22-000120 · edgar.xml · derivative · entry 1 LIDDY EDWARD M · CIK 0001188983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,024 Underlying: Common Stock · 212 shares Expires not disclosed F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2021 Filed Jan 5, 2022 22:27 UTC |
Strom Carrie CSVP & Pres Global Allerg Aesth
|
Tax withholdingCommon Stock, $0.01 par value | 10,336 | $135.93 | $1,404,972.48 |
DisclosureSEC source: 0001179110-22-000262 · edgar.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,711 Read SEC document |
| December 27, 2021 Filed Dec 30, 2021 22:01 UTC |
SEVERINO MICHAELVice Chairman
|
GiftCommon Stock, $0.01 par value | 583 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-011274 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,252 Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 22:01 UTC |
Schumacher Laura JVice Chairman
|
GiftCommon Stock, $0.01 par value | 15,905 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-011230 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,098 Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 22:29 UTC |
Durkin Brian LVP, Controller
|
Exercise / conversionOption (right to buy) · Derivative | 7,180 | $61.36 Strike: $0.00 | $440,564.80 |
DisclosureSEC source: 0001179110-21-011176 · edgar.xml · derivative · entry 3 Durkin Brian L · CIK 0001756865 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,180 shares Expires 2027-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.